These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 8523059)

  • 1. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):631-4. PubMed ID: 9681533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
    Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
    J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.
    Kantoff PW; Halabi S; Farmer DA; Hayes DF; Vogelzang NA; Small EJ
    J Clin Oncol; 2001 Jun; 19(12):3025-8. PubMed ID: 11408497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
    Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.
    Oudard S; Banu E; Scotte F; Banu A; Medioni J; Beuzeboc P; Joly F; Ferrero JM; Goldwasser F; Andrieu JM
    Ann Oncol; 2007 Nov; 18(11):1828-33. PubMed ID: 17846024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
    D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
    J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
    Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
    Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
    Daskivich TJ; Regan MM; Oh WK
    Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
    Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
    Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
    J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.
    Smith DC; Dunn RL; Strawderman MS; Pienta KJ
    J Clin Oncol; 1998 May; 16(5):1835-43. PubMed ID: 9586898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
    Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
    D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
    Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
    Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
    Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.